🚨#FDAApproval alert! 📢 FDA approves Daratumumab and Hyaluronidase-fihj (Darzalex Faspro®, Janssen Biotech, Inc.) for patients with high-risk smoldering multiple myeloma. 🧬 Approval based on the AQUILA trial with 390 patients — showing strong efficacy as monotherapy vs active monitoring.

🧮Calculate Khorana Score in seconds with ONCOassist #KhoranaScore #VTErisk #CancerThrombosis #OncologyTools #Oncoalert #ONCOassist

🚨New in #Oncology! Phase 3 Trial Results: 📊 Omitting postmastectomy chest-wall irradiation in intermediate-risk breast cancer patients showed no significant difference in 10-year OS, compared to those who received radiation. 💡 Findings shed new light on treatment de-escalation after mastectomy.

🚨New in #Oncology! 🎯 First randomized trial in older adults (70–80 yrs) with HER2+ breast cancer validates HER2DX genomic tool. 📊 Predicts long-term survival and supports tailored, chemo-sparing treatment strategies. 🔗 Read more: bit.ly/ONCOnews5O-2

🚨New in #Oncology! Phase 3 TRYBECA-1 Trial Update for Advanced Pancreatic Adenocarcinoma! 🔬 Eryaspase + chemotherapy vs chemotherapy alone in second-line treatment for advanced pancreatic adenocarcinoma — evaluating potential survival benefit and treatment outcomes.

Katy Winckworth-Prejsnar shares how @NCCN is adapting its oncology guidelines for global use. Watch the clip 🎥 : youtu.be/GYKqsiKxrig #Oncology #GlobalHealth #NCCN #CancerCare #OncologySpotlight #Oncoalert #NCCNguidelines

🚨New in #Oncology! 🎯 Servier’s VORANIGO® (vorasidenib) shows durable treatment benefit in long-term Phase III INDIGO trial. 📄 Findings from the extended analysis confirm continued efficacy in patients with IDH-mutant low-grade glioma — now published in The Lancet Oncology.

🚨New in #Oncology! 📢 23-Year Follow-up Results from the ERSPC! 💡The ERSPC trial, launched in 1993, provides long-term insights into the impact of PSA testing on prostate cancer mortality — offering critical data to evaluate the benefits and risks of routine screening.

🧮Calculate Clinical Treatment Score 5 (CTS5) in seconds with ONCOassist #breastcancerawareness 🎀 #ONCOassist #CTS5 #BreastCancer #CancerCare #ClinicalCalculator #ERPositive #HormoneReceptorPositive #OncologyApp #oncoalert

🚨New in #Oncology! 🧬 Phase 3 LEAP-012 Trial Update! Merck & Eisai share results from the Phase 3 LEAP-012 study evaluating KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) in combination with TACE for patients with unresectable, non-metastatic hepatocellular carcinoma (HCC).

🚨New in #Oncology! ✅ KEYTRUDA(pembrolizumab) monotherapy now approved by European Commission as neoadjuvant treatment, continued as adjuvant therapy with radiotherapy (with or without cisplatin). 📊 Based on Phase 3 KEYNOTE-689, marking the first and only anti–PD-1 therapy approved in this setting!

🚨New in #Oncology! 🔹 Ferring showcases new real-world evidence for ADSTILADRIN® (nadofaragene firadenovec-vncg) in clinical practice. 🔹 3 abstracts to be presented at the 101st Annual Meeting of the Western Section AUA, including data from the ABLE-41 real-world study on bladder cancer patients.

🚨Breaking: Phase III Study Update! ✅ Merck’s KEYTRUDA® (pembrolizumab) + WELIREG® (belzutifan) combo met its primary endpoint of DFS in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. 💥 LITESPARK-022 marks the second positive Phase 3 trial for WELIREG in RCC.

🚨Breaking: Phase III Study Update! ✅ WELIREG® (belzutifan) + LENVIMA® (lenvatinib) significantly improved PFS in previously treated advanced RCC patients. 💡 The groundbreaking LITESPARK-011 Phase 3 trial is the first to show a clear PFS advantage with a HIF-2α inhibitor + VEGF TKI combo.

🎥 New on #OncologyBytes Dr Banna & Dr Kanesvaran reflect on a record-breaking urology cancer summit: 🧠 Mini-orals, 1100+ global participants, new IUCS Association 📺 Watch: youtu.be/Z-Q4xr0F6tY #ONCOassist #PrecisionOncology #CancerCare #GUoncology #ONCOassist #CancerCare #IUCS2025 #Oncoalert ]

🚨FDA approval alert! ✅ The FDA approves Revumenib (Revuforj) for relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation. 💡 Approved for adult and pediatric patients (≥1 year) who have no satisfactory alternative treatment options. 🔗 Read more: bit.ly/ONCOnews27O-1

🔍Explore the Advanced Breast Cancer Tool in ONCOassist #breastcancerawareness 🎀 A quick, evidence-based aid for treatment decision support in metastatic breast cancer. #ONCOassist #AdvancedBreastCancer #BreastCancer #ABCTool #OncologyTools #ClinicalCalculator

🚨New in #Oncology! 🔬 FDA grants fast track designation to MT-125 for Glioblastoma, Phase 1/2 trial underway evaluating safety & preliminary activity. 🧠 MT-125 is an investigational myosin IIA/IIB inhibitor, already holding Orphan Drug status for malignant gliomas 🔗 Read more: bit.ly/ONCOnews24O-2

🚨FDA approval alert! ✅ FDA Approves Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for Relapsed/Refractory Multiple Myeloma 🔗 Read more: bit.ly/ONCOnews24O-1 #ONCOnews #OncoAlert #OncEd #Oncology #FDAApproval #MultipleMyeloma #CancerResearch

🚨BREAKING: 📊 The ACP reviewed 5 performance measures for colorectal cancer screening and surveillance — supporting only 1 as valid. ✅ The ACP Performance Measurement Committee found the “Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy” measure valid.

✨#ESMO25✨ 🚨 BREAKING: ESMO Unveils AI Safety Framework for Oncology! 💡 A new 3-tier framework sets safety standards for large language models (LLMs) in oncology — helping patients, clinicians, and institutions adopt AI tools responsibly. 🔗 Read more: bit.ly/ONCOnews23O-1

🎬That’s a wrap from #ESMO25 Incredible few days connecting with oncology professionals, pharma leaders & our amazing ONCOassist community. Thank you for the energy, ideas & feedback. Can’t wait for ESMO 2026! 📷 #ESMO2025 #Oncology #OncoAlert #OncTwitter

✨#ESMO25✨ 🚨BREAKING: Phase 3 Trial Update! 🎯 Camrelizumab + Famitinib combo significantly improved survival vs platinum-based chemotherapy in recurrent/metastatic cervical cancer. ➡️ Findings from the ESMO 2025 presentation highlights its potential as a new frontline treatment option for patients.

✨#ESMO25✨ 🚨 BREAKING: Phase 3 ALINA Study Update! 🫁 Alecensa (alectinib) achieved a 98.4% 4-year overall survival rate in resected ALK-positive early-stage NSCLC. ✅ Showed a 65% reduction in recurrence risk compared with chemotherapy, as presented at ESMO 2025. 🔗 Read more: bit.ly/ONCOnews22O-1

✨#ESMO25✨ 🚨BREAKING: SERENA-6 Trial Results! 🎗️ Switching to the camizestrant + CDK4/6 inhibitor in patients with ESR1-mutated advanced breast cancer delayed deterioration in pain, symptoms, and overall quality of life vs. AI-CDK4/6i. 🔗 Read more: bit.ly/ONCOnews21O-2 #ONCOnews #OncoAlert #OncEd

🎥 New on #OncologyBytes Dr. Petros Grivas at #IUCS2025 discusses global equity, biomarkers, & patient-centeed care in GU cancers. “Collaboration is key to moving the field forward.” 📺 Watch: youtu.be/hB-__9aagnU #ONCOassist #PrecisionOncology #CancerCare #GUoncology #ONCOassist #CancerCare

✨#ESMO25✨ 🚨BREAKING: KEYTRUDA® (pembrolizumab) shows long-term survival benefit in early & advanced NSCLC! 🫁 5–10 year follow-up from KEYNOTE trials confirms durable improvements in overall & event-free survival. 🔗 Read more: bit.ly/ONCOnews21O-1 #ONCOnews #OncoAlert #OncEd #ESMO2025 #NSCLC

🌟 Day 4 was exciting and full of new connections at #ESMO25! Thanks to everyone who visited the ONCOassist booth 🤝 Looking forward to seeing you all on the final day of ESMO 2025. #OncoAlert #ONCOassist #OncEd #myESMOStory #OncTwitter #ESMO2025 #Berlin #Germany

✨#ESMO25✨ 🚨 BREAKING: STELLAR-303 Phase 3 Update! 💊 Zanzalintinib + Atezolizumab (Tecentriq®) improved median OS to 10.9 months vs 9.4 months with regorafenib in metastatic colorectal cancer. 📈 The combination demonstrated a notable survival advantage in the intention-to-treat population.

✨#ESMO25✨ 🚨BREAKING: ESMO 2025 Update! 💉 Disitamab Vedotin + Toripalimab shows encouraging activity in HER2+ advanced urothelial cancer 🔬 HER2-targeted ADC therapy, alone or with PD-1 immunotherapy, demonstrates meaningful antitumor response with manageable safety 🔗 bit.ly/ONCOnews20O-4

✨#ESMO25✨ 🚨BREAKING: ESMO 2025 Update! 🧬 Sacituzumab Tirumotecan (sac-TMT) demonstrates notable survival benefits in EGFR-mutated advanced NSCLC resistant to EGFR-TKI and platinum-based therapy. 🌟 An antibody–drug conjugate targeting TROP2, offering new potential for patients.

✨#ESMO25✨ 🚨BREAKING: ESMO 2025 Update! 💥 Roche’s Tecentriq® (atezolizumab) shows significant overall & disease-free survival benefits in bladder cancer with ctDNA-guided treatment. 🌍 IMvigor011 — the first global Phase III trial pioneering ctDNA-guided post-surgery therapy in MIBC.

✨ Day 3 at #ESMO25 had been incredible! Thanks to everyone who visited the ONCOassist booth. Looking forward to seeing everyone on Day 4. #ONCOassist #OncoAlert #OncEd #myESMOStory #OncTwitter #ESMO2025 #Berlin #Germany

✨#ESMO25✨ 🚨BREAKING: KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma 📈 Durable Benefit: 5-year OS results in the pMMR subgroup are consistent with the overall population. 💡 Improved Outcomes: OS rate of 19.9% with KEYTRUDA + LENVIMA vs. 7.7% with chemotherapy.

✨#ESMO25✨ 🚨BREAKING: PADCEV™(enfortumab vedotin) + KEYTRUDA™(pembrolizumab) in MIBC ➡️ First and only perioperative combo to improve survival in cisplatin-ineligible patients. 📊 Phase 3 EV-303 trial shows 60% lower risk of recurrence or progression and 50% improvement in overall outcomes.

✨#ESMO25✨ 🚨BREAKING: 9-Year CheckMate 238 Results! 🩸 Nivolumab shows longer recurrence-free survival vs. ipilimumab in patients with resected stage III/IV melanoma. ⏳ First long-term data highlight durable benefits of immunotherapy in melanoma. 🔗 Read more: bit.ly/ONCOnews19O-5

✨#ESMO25✨ 🚨 BREAKING: DESTINY-Breast05 Phase III Results! 🎗️ Enhertu (trastuzumab deruxtecan) reduced the risk of recurrence or death by 53% vs. T-DM1 in high-risk HER2+ early breast cancer after neoadjuvant therapy. 🌟 Over 92% of patients on Enhertu remained free of invasive disease at 3 years.

✨#ESMO25✨ 🚨 BREAKING: MARIPOSA Trial – Final OS Results! 💊 Rybrevant (amivantamab) – lazertinib shows promise in EGFR-mutated advanced NSCLC as first-line therapy. ✅ Approved by the European Medicines Agency for advanced NSCLC. 🔗 Read more: bit.ly/ONCOnews19O-3

✨#ESMO25✨ 🚨BREAKING: EPIK-O/ENGOT-ov61 Trial Update! 💊 Alpelisib + Olaparib vs Chemotherapy in platinum-resistant/refractory high-grade serous ovarian cancer (HGSOC) without BRCA mutation 🌟 Highlighting new insights for patients with limited treatment options. 🔗 Read more: bit.ly/ONCOnews19O-2

✨#ESMO25✨ 🚨BREAKING: VIKTORIA-1 Phase 3 Update! 🧬 The PIK3CA-mutant cohort in the Phase 3 VIKTORIA-1 trial is now fully enrolled. 📈 Phase 1b data show a median PFS of 14.6 months with gedatolisib + fulvestrant + palbociclib in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer.

✨ Day 2 at #ESMO2025 was all about exciting conversations and great energy. We’re thrilled to meet so many oncology professionals — join us again on Day 3! 🤝 #ONCOnews #OncoAlert #OncEd #myESMOStory #OncTwitter #ESMO25 #Berlin #Germany

✨#ESMO25✨ 🚨BREAKING: Zongertinib in Advanced HER2-Mutant NSCLC 🎯 Boehringer’s zongertinib showed a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC in the Phase Ib Beamion LUNG-1 trial at #ESMO25. 🔗 Read more: bit.ly/ONCOnews18O-4

✨#ESMO25✨ 🚨BREAKING: AMPLITUDE Trial Updates! 📊 Patient-reported outcomes from the AMPLITUDE trial evaluating Niraparib + Abiraterone Acetate + Prednisone in metastatic hormone-sensitive prostate cancer (mHSPC) patients with homologous recombination repair (HRR) mutations.

✨#ESMO25✨ 🚨BREAKING: Sevabertinib in Advanced HER2-Mutant NSCLC. ➡️ HER2 mutations occur in 2–4% of NSCLC patients. 💊 Sevabertinib, an oral reversible tyrosine kinase inhibitor, shows promising anti-HER2 activity in preclinical models. 🔗 Read more: bit.ly/ONCOnews18O-2

✨#ESMO25✨ 🚨BREAKING: Phase 3 Data! 📈 Osimertinib + chemotherapy significantly improved overall survival vs. Osimertinib alone in patients with EGFR-mutated advanced NSCLC. ✅ Reinforces its potential as a new first-line standard of care. 🔗 Read more: bit.ly/ONCOnews18O-1

✨#ESMO25✨ 🚨BREAKING: POTOMAC Phase 3 Update! ➡️ 32% lower risk of disease recurrence or death in high-risk non–muscle-invasive bladder cancer with Imfinzi(durvalumab) vs. BCG alone. ⏱️ 1year of Imfinzi added to BCG induction and maintenance delivered early and sustained disease-free survival benefit.

✨Inspiring conversations & new connections at #ESMO25! A big thank you to everyone who visited our booth. Excited for more learning, networking, and innovation on Day 2! #ONCOassist #OncoAlert #myESMOStory #ESMO2025 #OncologyUpdates #MedicalConference #Berlin #Germany #OncTwitter

✨#ESMO25✨ 🚨BREAKING: 5-Year NATALEE Data! ✅ Kisqali® (ribociclib) + endocrine therapy shows 28% reduction in recurrence risk in the broadest HR+/HER2- early breast cancer population. 💊 Demonstrates 29.1% risk reduction in distant disease-free survival with no new safety signals post-treatment.

✨#ESMO25✨ 🚨BREAKING: Phase 3 KEYNOTE-B96 Trial Results! ✅ Merck’s KEYNOTE-B96 met its secondary endpoint — showing a statistically significant improvement in OS in platinum-resistant recurrent ovarian cancer.

📢 BREAKING: Phase III REACH2 Trial! ➡️ Final Analysis: Evaluates efficacy and safety of Ruxolitinib versus best available therapy in steroid-refractory acute graft-versus-host disease. 🔬 Phase III Results: Provides insights into treatment outcomes and potential advantages over standard therapy.